Searched over 200M research papers for "losartan 100/25"
10 papers analyzed
These studies suggest that losartan 100 mg combined with hydrochlorothiazide 25 mg effectively reduces blood pressure, is well-tolerated, and is beneficial for patients with moderate to severe hypertension.
19 papers analyzed
Losartan, an angiotensin II receptor antagonist, is often combined with hydrochlorothiazide (HCTZ), a thiazide diuretic, to enhance antihypertensive efficacy. This combination is particularly beneficial for patients whose blood pressure is not adequately controlled by monotherapy.
Multiple studies have demonstrated the significant antihypertensive effects of the losartan 100 mg/HCTZ 25 mg combination. In a multicenter trial, patients with moderate-to-severe hypertension experienced a mean reduction in sitting diastolic blood pressure (DBP) by 17.5 mm Hg and systolic blood pressure (SBP) by 19.3 mm Hg after 8 weeks of treatment. Another study reported similar findings, with a reduction in DBP by 13.7 mm Hg and SBP by 19.3 mm Hg over 12 weeks.
When compared to other antihypertensive combinations, losartan/HCTZ has shown comparable or superior efficacy. For instance, a study comparing losartan/HCTZ with enalapril/HCTZ found that both combinations effectively reduced blood pressure, but losartan/HCTZ had a better tolerability profile and fewer side effects. Additionally, losartan/HCTZ was more effective in reducing central systolic blood pressure compared to bisoprolol/HCTZ, despite similar reductions in brachial blood pressure.
The combination of losartan 100 mg and HCTZ 25 mg is generally well-tolerated. In a study involving 446 patients, the incidence of adverse experiences was 34.7% for the losartan 100 mg/HCTZ 25 mg group, which was comparable to the placebo group. Another study reported that only 0.43% of patients experienced adverse events, with a very low discontinuation rate due to side effects.
Losartan/HCTZ has also been shown to have a favorable impact on metabolic and renal parameters. In a study involving high-risk patients, treatment with losartan/HCTZ led to improvements in fasting glucose, HbA1c, serum creatinine, and albumin in urine. Unlike enalapril/HCTZ, losartan/HCTZ did not increase serum uric acid levels, making it a safer option for patients with a predisposition to gout.
Long-term studies have confirmed the sustained efficacy of losartan/HCTZ in controlling blood pressure. In a 6-month trial, losartan/HCTZ achieved target office blood pressure in 96.9% of patients and target 24-hour blood pressure in 75% of patients. The combination therapy also maintained a high response rate, with 87.8% of patients showing significant blood pressure reductions.
A dose-response relationship has been observed with losartan, where higher doses result in greater blood pressure reductions. Patients treated with losartan 100 mg/HCTZ 25 mg showed more significant reductions in both systolic and diastolic pressures compared to lower doses .
The combination of losartan 100 mg and hydrochlorothiazide 25 mg is highly effective in reducing blood pressure in patients with moderate-to-severe hypertension. It offers a favorable safety profile, with minimal adverse effects and positive impacts on metabolic and renal parameters. This combination therapy is a valuable option for patients requiring enhanced blood pressure control, particularly those who do not respond adequately to monotherapy.
Most relevant research papers on this topic